Literature DB >> 12822128

Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.

David M Kent1, Donnie McGrath, John P A Ioannidis, Michael L Bennish.   

Abstract

The delivery of antiretroviral therapy in the developing world requires guidelines for the appropriate monitoring of therapy, including monitoring for treatment effectiveness and treatment failure, drug toxicities, adherence to therapy, and the emergence of resistant organisms. Guidelines developed in wealthy industrialized countries, which rely heavily on laboratory tests often unavailable in the developing world, may not be feasible or appropriate for resource-limited settings. Even if the standard of care routinely delivered in industrialized settings cannot be replicated, antiretroviral treatment programs with less-intense monitoring have the potential to reduce morbidity and mortality from human immunodeficiency virus. Research to identify monitoring strategies that provide the greatest benefit to those living with human immunodeficiency virus in resource-limited settings and that use the available technologies and resources needs to be conducted within a conceptual and ethical framework that takes into account differences between rich and poor countries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12822128     DOI: 10.1086/375368

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Assessment of laboratory test utilization for HIV/AIDS care in urban ART clinics of Lilongwe, Malawi.

Authors:  Sonali Palchaudhuri; Hannock Tweya; Mina Hosseinipour
Journal:  Malawi Med J       Date:  2014-06       Impact factor: 0.875

2.  Measuring markers of liver function using a micropatterned paper device designed for blood from a fingerstick.

Authors:  Sarah J Vella; Patrick Beattie; Rebecca Cademartiri; Anna Laromaine; Andres W Martinez; Scott T Phillips; Katherine A Mirica; George M Whitesides
Journal:  Anal Chem       Date:  2012-03-02       Impact factor: 6.986

3.  Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.

Authors:  Cheryl Jennings; Susan A Fiscus; Suzanne M Crowe; Aleksandra D Danilovic; Ralph J Morack; Salvatore Scianna; Ada Cachafeiro; Donald J Brambilla; Jorg Schupbach; Wendy Stevens; Richard Respess; Oliviero E Varnier; Gary E Corrigan; J Simon Gronowitz; Michael A Ussery; James W Bremer
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

4.  Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Maurizio de Martino
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

5.  Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

Authors:  S Saravanan; M Vidya; P Balakrishnan; P Balakrishanan; N Kumarasamy; Sunil S Solomon; S Solomon; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer
Journal:  J Virol Methods       Date:  2009-04-02       Impact factor: 2.014

6.  Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression.

Authors:  Elijah Paintsil; Musie Ghebremichael; Sostena Romano; Warren A Andiman
Journal:  Pediatr Infect Dis J       Date:  2008-07       Impact factor: 2.129

7.  Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.

Authors:  Antonieta Medina Lara; Jesse Kigozi; Jovita Amurwon; Lazarus Muchabaiwa; Barbara Nyanzi Wakaholi; Ruben E Mujica Mota; A Sarah Walker; Ronnie Kasirye; Francis Ssali; Andrew Reid; Heiner Grosskurth; Abdel G Babiker; Cissy Kityo; Elly Katabira; Paula Munderi; Peter Mugyenyi; James Hakim; Janet Darbyshire; Diana M Gibb; Charles F Gilks
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

9.  Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.

Authors:  Gonzague Jourdain; Sophie Le Cœur; Nicole Ngo-Giang-Huong; Patrinee Traisathit; Tim R Cressey; Federica Fregonese; Baptiste Leurent; Intira J Collins; Malee Techapornroong; Sukit Banchongkit; Sudanee Buranabanjasatean; Guttiga Halue; Ampaipith Nilmanat; Nuananong Luekamlung; Virat Klinbuayaem; Apichat Chutanunta; Pacharee Kantipong; Chureeratana Bowonwatanuwong; Rittha Lertkoonalak; Prattana Leenasirimakul; Somboon Tansuphasawasdikul; Pensiriwan Sang-A-Gad; Panita Pathipvanich; Srisuda Thongbuaban; Pakorn Wittayapraparat; Naree Eiamsirikit; Yuwadee Buranawanitchakorn; Naruepon Yutthakasemsunt; Narong Winiyakul; Luc Decker; Sylvaine Barbier; Suporn Koetsawang; Wasna Sirirungsi; Kenneth McIntosh; Sombat Thanprasertsuk; Marc Lallemant
Journal:  PLoS Med       Date:  2013-08-06       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.